Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALA NASDAQ:CTMX NYSE:LCI NASDAQ:MGTA NASDAQ:MRSN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALACalithera Biosciences$0.00$0.00▼$0.01N/A-38,611 shs3 shsCTMXCytomX Therapeutics$3.26-1.2%$2.62$0.40▼$3.91$537.62M2.273.75 million shs1.74 million shsLCILannett$1.54$0.64▼$3.72$7.38M0.9592,067 shs280,600 shsMGTAMagenta Therapeutics$0.70-7.7%$0.53$0.32▼$2.07$42.44M2.12848,835 shs376,000 shsMRSNMersana Therapeutics$9.78-0.4%$8.09$5.21▼$70.75$48.81M0.969,631 shs30,479 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALACalithera Biosciences0.00%0.00%0.00%0.00%-99.00%CTMXCytomX Therapeutics0.00%+1.87%+14.79%+35.83%+201.85%LCILannett0.00%0.00%0.00%0.00%0.00%MGTAMagenta Therapeutics0.00%0.00%0.00%0.00%0.00%MRSNMersana Therapeutics0.00%-1.01%+36.40%+21.45%-81.01%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALACalithera Biosciences$0.00$0.00▼$0.01N/A-38,611 shs3 shsCTMXCytomX Therapeutics$3.26-1.2%$2.62$0.40▼$3.91$537.62M2.273.75 million shs1.74 million shsLCILannett$1.54$0.64▼$3.72$7.38M0.9592,067 shs280,600 shsMGTAMagenta Therapeutics$0.70-7.7%$0.53$0.32▼$2.07$42.44M2.12848,835 shs376,000 shsMRSNMersana Therapeutics$9.78-0.4%$8.09$5.21▼$70.75$48.81M0.969,631 shs30,479 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALACalithera Biosciences0.00%0.00%0.00%0.00%-99.00%CTMXCytomX Therapeutics0.00%+1.87%+14.79%+35.83%+201.85%LCILannett0.00%0.00%0.00%0.00%0.00%MGTAMagenta Therapeutics0.00%0.00%0.00%0.00%0.00%MRSNMersana Therapeutics0.00%-1.01%+36.40%+21.45%-81.01%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALACalithera Biosciences 0.00N/AN/AN/ACTMXCytomX Therapeutics 2.86Moderate Buy$5.8378.94% UpsideLCILannett 0.00N/AN/AN/AMGTAMagenta Therapeutics 0.00N/AN/AN/AMRSNMersana Therapeutics 2.71Moderate Buy$56.60478.73% UpsideCurrent Analyst Ratings BreakdownLatest CALA, MRSN, LCI, MGTA, and CTMX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025MRSNMersana TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/24/2025CTMXCytomX TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/21/2025CTMXCytomX TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$3.50 ➝ $6.0010/8/2025CTMXCytomX TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)10/8/2025MRSNMersana TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025CTMXCytomX TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/27/2025MRSNMersana TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/22/2025CTMXCytomX TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$6.009/22/2025CTMXCytomX TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$6.009/17/2025CTMXCytomX TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$3.509/16/2025CTMXCytomX TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 10/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALACalithera BiosciencesN/AN/AN/AN/AN/AN/ACTMXCytomX Therapeutics$138.10M3.89$0.36 per share9.01($0.01) per share-326.00LCILannett$340.58M0.00N/AN/A($23.34) per share0.00MGTAMagenta TherapeuticsN/AN/AN/AN/A$1.23 per shareN/AMRSNMersana Therapeutics$40.50M1.20N/AN/A($1.92) per share-5.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALACalithera Biosciences-$39.65M-$2.010.00N/AN/AN/AN/AN/AN/ACTMXCytomX Therapeutics$31.87M$0.565.82N/AN/A34.04%158.70%36.04%11/6/2025 (Estimated)LCILannett-$231.62M-$18.88N/AN/AN/A-62.40%N/A-13.39%N/AMGTAMagenta Therapeutics-$76.46MN/A0.00∞N/AN/A-70.88%-57.27%N/AMRSNMersana Therapeutics-$69.19M-$14.62N/AN/AN/A-212.94%N/A-54.85%11/12/2025 (Estimated)Latest CALA, MRSN, LCI, MGTA, and CTMX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025MRSNMersana Therapeutics-$1.44N/AN/AN/A$14.20 millionN/A11/6/2025Q3 2025CTMXCytomX Therapeutics-$0.04N/AN/AN/A$11.50 millionN/A8/13/2025Q2 2025MRSNMersana Therapeutics-$3.75-$4.08-$0.33-$4.87$6.06 million$3.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALACalithera BiosciencesN/AN/AN/AN/AN/ACTMXCytomX TherapeuticsN/AN/AN/AN/AN/ALCILannettN/AN/AN/AN/AN/AMGTAMagenta TherapeuticsN/AN/AN/AN/AN/AMRSNMersana TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALACalithera BiosciencesN/AN/AN/ACTMXCytomX TherapeuticsN/A4.204.20LCILannettN/A2.231.39MGTAMagenta TherapeuticsN/A19.4919.49MRSNMersana TherapeuticsN/A1.351.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALACalithera BiosciencesN/ACTMXCytomX Therapeutics67.77%LCILannett40.28%MGTAMagenta Therapeutics47.53%MRSNMersana Therapeutics93.92%Insider OwnershipCompanyInsider OwnershipCALACalithera Biosciences6.60%CTMXCytomX Therapeutics6.60%LCILannett13.12%MGTAMagenta Therapeutics15.18%MRSNMersana Therapeutics13.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALACalithera Biosciences604.87 million4.55 millionNot OptionableCTMXCytomX Therapeutics170164.91 million154.03 millionOptionableLCILannett81010.77 million9.35 millionOptionableMGTAMagenta Therapeutics6760.67 million51.46 millionNot OptionableMRSNMersana Therapeutics1504.99 million4.34 millionOptionableCALA, MRSN, LCI, MGTA, and CTMX HeadlinesRecent News About These CompaniesMartin Jr. Huber Sells 2,012 Shares of Mersana Therapeutics (NASDAQ:MRSN) StockSeptember 16, 2025 | insidertrades.comWall Street Analysts See a 314.81% Upside in Mersana Therapeutics (MRSN): Can the Stock Really Move This High?September 8, 2025 | zacks.comMersana Therapeutics Faces Nasdaq Non-Compliance NoticeSeptember 6, 2025 | msn.comWall Street Analysts Think Mersana Therapeutics (MRSN) Could Surge 248.83%: Read This Before Placing a BetAugust 22, 2025 | zacks.comMersana Therapeutics price target adjusted to $36 at Truist after reverse splitAugust 14, 2025 | msn.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | insidermonkey.comMersana Therapeutics Reports Q2 2025 Financial ResultsAugust 14, 2025 | msn.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | msn.comMersana Therapeutics reports Q2 EPS ($4.87), consensus ($4.25)August 13, 2025 | msn.comMersana Therapeutics, Inc. (MRSN) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | seekingalpha.comMersana Therapeutics, Inc.: Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial ResultsAugust 13, 2025 | finanznachrichten.deMersana Misses Fiscal Q2 Revenue TargetAugust 13, 2025 | theglobeandmail.comMersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial ResultsAugust 13, 2025 | finance.yahoo.comMersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue EstimatesAugust 13, 2025 | zacks.comMersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial ResultsAugust 13, 2025 | globenewswire.comMersana Therapeutics Q2 2025 Earnings PreviewAugust 12, 2025 | msn.comA Look at Mersana Therapeutics's Upcoming Earnings ReportAugust 12, 2025 | benzinga.comEarnings To Watch: Mersana Therapeutics Inc (MRSN) Reports Q2 2025 ResultAugust 12, 2025 | finance.yahoo.comMersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025August 6, 2025 | globenewswire.comMersana Therapeutics trading halted, news pendingJuly 26, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCALA, MRSN, LCI, MGTA, and CTMX Company DescriptionsCalithera Biosciences NASDAQ:CALACalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.CytomX Therapeutics NASDAQ:CTMX$3.26 -0.04 (-1.21%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$3.33 +0.07 (+2.12%) As of 10/24/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Lannett NYSE:LCILannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.Magenta Therapeutics NASDAQ:MGTAMagenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation. Its product candidates are designed to bring the curative power of stem cell transplant to patients with blood cancers, genetic diseases, and autoimmune diseases. The company's product portfolio includes MGTA-117, an anti-CD117 antibody conjugated to an amanitin payload that targets hematopoietic stem cells (HSCs) and leukemia cells; and MGTA-45, an anti-human CD45 antibody conjugated to a DNA-interacting payload for HSCs, leukemia cells, and immune cells. In addition, it focus on development of ADC-based conditioning program that targets a receptor of T cells; and novel conditioning and translation stem cell sciences, as well as develops cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. In addition, the company has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. Magenta Therapeutics, Inc. was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Mersana Therapeutics NASDAQ:MRSN$9.78 -0.04 (-0.41%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$9.94 +0.16 (+1.58%) As of 10/24/2025 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
